Differential response to a selective cannabinoid receptor antagonist (SR141716: Rimonabant) in female mice from lines selectively bred for high voluntary wheel-running behaviour

Behavioural Pharmacology

Volumn 19, Issue 8, 2008, Pages 812-820

  Keeney, Brooke K ^a   Raichlen, David A ^b   Meek, Thomas H ^a   Wijeratne, Rashmi S ^a   Middleton, Kevin M ^a,c   Gerdeman, Gregory L ^b,d   Garland Jr , Theodore ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c CALIFORNIA STATE UNIVERSITY   (United States)

^d ECKERD COLLEGE   (United States)

Author keywords

Artificial selection; Endocannabinoids; Exercise; Experimental evolution; Genetics; Hyperactivity; Locomotor acitivity; Mouse; Rimonabant; Sex differences; Wheel running

Indexed keywords

CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BREEDING LINE; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; EXERCISE; FEMALE; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PROTEIN FUNCTION; REWARD; RUNNING; SEX DIFFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; BEHAVIOR, ANIMAL; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; MOTOR ACTIVITY; PIPERIDINES; PYRAZOLES; SELECTION (GENETICS); SEX CHARACTERISTICS; TIME FACTORS;

EID: 57149123143     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32831c3b6b     Document Type: Article

References (76)

1. Alvarez-Jaimes L, Polis I, Parsons LH (2008). Attenuation of cue-induced heroin-seeking behavior by cannabinoid CB1 antagonist infusions into the nucleus accumbens core and prefrontal cortex, but not basolateral amygdala Neuropsychopharmacology 33:2483-2493.
2. Belke TW (1996). Investigating the reinforcing properties of running: or, running is its own reward. In: Epling WF, Pierce WD, editors. Activity anorexia: theory, research, and treatment. Mahwah, NJ: Lawrence Erlbaum Associates; pp. 45-55.
3. Belke TW, Garland T Jr (2007). A brief opportunity to run does not function as a reinforcer for mice selected for high daily wheel-running rates. J Exp Anal Behav 88:199-213.
4. Belke TW, Heyman GM (1994). A matching law analysis of the reinforcing efficacy of wheel running in rats. Anim Learn Behav 22:267-274.
5. Brady KT, Randall C (1999). Gender differences in substance use disorders. Psychiatr Clin N Am 22:241-252.
6. Bronikowski AM, Carter PA, Swallow JG, Girard IA, Rhodes JS, Garland T Jr (2001). Open-field behavior of house mice selectively bred for high voluntary wheel-running. Behav Genet 31:309-316.
7. Carai MAM, Colombo G, Gessa GL (2005). Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci 77:2339-2350.
8. Carter PA, Swallow JG, Davis SJ, Garland T Jr (2000). Nesting behavior of house mice (Mus domesticus) selected for increased wheel-running activity. Behav Genet 30:85-94.
9. Cheer JF, Wassum KM, Sombers LA, Heien MLAV, Ariansen JL, Aragona BJ, et al. (2007). Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neuroscience 27:791-795.
10. Cohen C, Perrault G, Griebel G, Soubrie P (2005). Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 30:145-155.
11. Cohn RA, Baratt E, Pirch JH (1972). Differences in behavioral responses of male and female rats to marijuana. Proc Soc Exp Biol Med 140:1136-1139.
12. Coimbra NC, Castro-Souza C, Segato EN, Nora JEP, Herrero CFPS, Tedeschi-Filho W, Garcia-Cairasco N (2001). Post-ictal analgesia: Involvement of opioid, serotoninergic and cholinergic mechanisms. Brain Res 888:314-320.
13. Compton DR, Aceto MD, Lowe J, Martin BR (1996). In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): Inhibition of DELTA-9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594.
14. Corbille A-G, Valjent E, Marsicano G, Ledent C, Lutz B, Herve D, Girault J-A (2007). Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J Neurosci 27:6937-6947.
15. Cota D, Woods SC (2005). The role of the endocannabinoid system in the regulation of energy homeostasis. Curr Opin Endocrinol Diab 12:338-351.
16. Craft RM (2005). Sex differences in behavioral effects of cannabinoids. Life Sci 77:2471-2478.
17. De Petrocellis L, Cascio MG, Di Marzo V (2004). The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141:765-774.
18. De Vries TJ, Schoffelmeer ANM (2005). Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol Sci 26:420-426.
19. Demuth DG, Molleman A (2006). Cannabinoid signalling. Life Sci 78:549-563.
20. Dietrich A, McDaniel WF (2004). Endocannabinoids and exercise. Br J Sports Med 38:536-541.
21. Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W (2007). Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br J Pharmacol 152:795-804.
22. Foltin RW, Haney M (2007). Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates. Pharmacol Biochem Behav 86:766-773.
23. Gammie SC, Hasen NS, Rhodes JS, Girard I, Garland T Jr (2003). Predatory aggression, but not maternal or intermale aggression, is associated with high voluntary wheel-running behavior in mice. Horm Behav 44:209-221.
24. Garland T Jr (2003). Selection experiments: an under-utilized tool in biomechanics and organismal biology. In: Bels VL, Gasc J-P, Casinos A, editors. Vertebrate biomechanics and evolution. Oxford, UK: BIOS Scientific Publishers; pp 23-56.
25. Gerdeman GL, Schechter JB, French ED (2008). Context-specific reversal of cocaine sensitization by the CB(1) cannabinoid receptor antagonist rimonabant. Neuropsychopharmacology 33:2747-2759.
26. Girard I, Garland T Jr (2002). Plasma corticosterone response to acute and chronic voluntary exercise in female house mice. J Appl Physiol 92: 1553-1561.
27. Girard I, McAleer MW, Rhodes JS, Garland T Jr (2001). Selection for high voluntary wheel running increases speed and intermittency in house mice (Mus domesticus). J Exp Biol 204:4311-4320.
28. Gonzales S, Bisogno T, Wenger T, Manzanares J, Milone A. Berrondero F, et al. (2000). Sex ateroid influence on cannabinoid CB1 receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Biochem Biophys Res Commun 270:260-266.
29. Hoffman MD, Shepanski MA, Ruble SB, Valic Z, Buckwalter JB, Clifford PS (2004). Intensity and duration threshold for aerobic exercise-induced analgesia to pressure pain. Arch Phys Med Rehabil 85:1183-1187. Hohmann A, Suplita R (2006). Endocannabinoid mechanisms of pain modulation. AAPS J 8:E693-E708.
30. Isoldi KK, Aronne LJ (2008). The challenge of treating obesity: the endocannabinoid system as a potential target. J Am Diet Assoc 108:823-831.
31. Kelley AE (2004). Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 44:161-179.
32. Koteja P, Garland T Jr (2001). Forum: response to R. Eikelboom. Anim Behav 61:F25-F26.
33. Laviotette SR, Grace AA (2006). The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci 63:1597-1613.
34. Li G, Rhodes JS, Girard I, Gammie SC, Garland T Jr (2004). Optoid-mediated pain sensitivity in mice bred for high voluntary wheel running. Physiol Behav 83:515-524.
35. Lichtman AH, Cook SA, Martin BR (1996). Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 276:585-593.
36. Lupica CR, Riegel AC (2005). Endocannabinoid release from midbrain dopamine neurons: A potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 48:1105-1116.
37. Lynch WJ (2006). Sex differences in vulnerability to drug self-administration. Exp Clin Psychopharmacol 14:34-41.
38. Mahler SV, Smith KS, Berridge KC (2007). Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbene shell enhances 'liking' of a sweet reward. Neuropsychopharmacology 32:2267-2278.
39. Makela P, Wakeley J, Gijsman H, Robson PJ, Bhagwagar Z, Rogers RD (2006). Low doses of D-9 tetrahydrocannabinol (THC) have divergent effects on short-term spatial memory in young, healthy adults. Neuropsychopharmacology 31: 462-470.
40. Maldonado R, Valverde O, Berrendero F (2006). Involvement of the endocannabinoid system in drug addiction. TrendsNeurosci 29:225-232.
41. Malisch JL, Brauner CW, Gomes FR, Chapped MA, Garland T Jr (2008). Circadian pattern of total and free corticosterone concentrations, corticosteroid-binding globulin, and physical activity in mice selectively bred for high voluntary wheel-running behavior. General Comp Endocrinol 156: 210-217.
42. Matrtew RJ, Wilson WH, Davis R (2003). Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. Pharmacol, Biochem Behav 75:309-318.
43. McGregor IS, Arnold JC (2007). Cannabis reward: biased towards the fairer sex? Br J Pharmacol 152:562-564.
44. Morgan WP (1979). Negative addiction in runners. Physician Sports Med 7: 7-70.
45. Onaivi ES, Chaudhuri G, Abaci AS, Parker M, Manier DH, Martin PR, Hubbard JR (1999). Expression of cannabinoid receptors and their gene transcripts in human blood cells. Prog Neuropsychopharmacol Biol Psychiatry 23: 1063-1077.
46. Pacher P, Batkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462.
47. Pagotto U, Cervino C, Vicennati V, Marsicano G, Lutz B, Pasquali R (2006). How many sites of action for endocannabinoids to control energy metabolism? Int J Obesity 30:S39-S43.
48. Patel S, Hillard CJ (2006). Pharmacological evaluation of cannabinoid receptor liganda in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318:304-311.
49. Pillolla G, Melis M, Perra S, Muntoni AL, Gessa GL, Pistis M (2007). Medial forebrain bundle stimulation evokes endocannabinoid-mediated modulation of ventral tegmental area dopamine neuron firing in vivo. Psyohopharmacology 191:843-853.
50. Premack D, Schaeffer RW, Hundt A (1964). Reinforcement of drinking by running: Effect of fixed ratio and reinforcement time. J Exp Anal Behav 7: 91-96.
51. Rezende EL, Chappell MA, Gomes FR Malisch JL, Garland T Jr (2005). Maximal metabolic rates during voluntary exercise, forced exercise, and cold exposure in house mice selectively bred for high wheel-running. J Exp Biol 208: 2447-2458.
52. Rhodes JS, Gammie SC, Garland T Jr (2006). Neurobiology of mice selected for high voluntary wheel-running activity. Integr Comp Biol 48:438-455.
53. Rhodes JS, Garland T Jr (2003). Differential sensitivity to acute administration of ritalin, apormorphine, SCH 23380, but not raclopride in mice selectively bred for hyperactive wheel-running behavior. Psychopharmacology 167:242-250.
54. Rhodes JS, Garland T Jr, Gammie SC (2003). Patterns of brain activity associated with variation in voluntary wheel-running behavior. Behav Neurosci 117:1243-1266.
55. Rhodes JS, Hosack GR, Girard I, Keiley AE, Mitchell GS, Garland T Jr (2001). Differential sensitivity to acute administration of cocaine, GBR 12909, and fluoxetine in mice selectively bred for hyperactive wheel-running behavior. Paychopharmacology 158:120-131.
56. Rhodes JS, Koteja P, Swallow JG, Carter PA, Garland T Jr (2000). Body temperatures of house mice artificially selected for high voluntary wheel-running behavior: repeatability and effect of genetic selection. J Thermal Biol 25:391-400.
57. Richardson J (2000). Cannabinoids modulate pain by multiple mechanisms of action. J Pain 1:2-14.
58. Rodriguez de Fonseca F, Cebeira M, Ramos JA, Martin M, Fernandez-Ruiz JJ (1994). Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during the estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci 54:169-170.
59. Russo EB (2004). Clinical endocannabinoid deficiency (CECO): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinol Lett 25:31-39.
60. Sherwin CM (1998). Voluntary wheel running: a review and novel interpretation. Animal Behaviour 56:11-27.
61. Sherwin CM, Nicol CJ (1996). Reorganization of behaviour in laboratory mice, Mus musculus, with varying cost of access to resources. Animal Behaviour 51:1087-1093.
62. Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A (2003). Exercise activates the endocannabinoid system. NeuroReport 14:2209-2211.
63. Steiner MA, Wanisch K, Monory K, Marsicano G, Borroni E, Bachli H, et al. (2007). Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenomica J 8:196-208.
64. Swallow JG, Carter PA, Garland T Jr (1998). Artificial selection for increased wheel-running behavior in house mice. Behav Genet 28:227-237.
65. Swallow JG, Koteja P, Carter PA, Garland T Jr (1999). Artificial selection for increased wheel-running activity in house mice results in decreased body mass at maturity. J Exp Biol 202:2513-2520.
66. Thornton-Jones ZD, Vickers SP, Clifton PG (2005). The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food. Psychopharmacology 179:452-460.
67. Timberlake W, Wozny M (1979). Reversibility of reinforcement between eating and running by schedule changes - comparison of hypotheses and models. Anim Learn Behav 7:461-469.
68. Tseng AH, Craft RM (2001). Sex differences in antinociceptive and motoric effects of cannabinoide. Eur J Pharmacol 430:41-47.
69. Tzavara ET, Devis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, et al. (2003). The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138:544-553.
70. Vaanholt LM, Meerlo P, Garland T Jr, Visser GH, van Dijk G (2007). Plasma adiponectin is increased in mice selectively bred for high wheel-running activity, but not by wheel running per se. Horm Metab Res 39:377-383.
71. Van Laere K, Goffin K, Casteels C, Dupont P, Mortelmans L, de Hoon J, Bormans G (2008). Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [F-18]MK-9470 PET. NeuroImage 39:1533-1541.
72. Ward SJ, Walker EA, Dykstra LA (2007). Effect of cannabinoid CB1 receptor antagonist SR141714A and CS1 receptor knockout on cue-induced reinstatement of Ensure® and corn-oil seeking in mice. Neuropsyohopharmacology 32:2592-2600.
73. Wiley JL (2003). Sex-dependent effects of DELTA9-tetrahydrocannabinol on locomotor activity in mice. Neurosci Lett 352:77-80.
74. Wu X, French ED (2000). Effects of chronic DELTA 9-tetrahydrocannabinol on rat midbrain dopamine neurons: an etectrophysiotogical assessment. Neuropharmacology 39:391-398.
75. Xi Z-X, Newman AH, Gilbert JG, Pak AC, Peng X-Q, Ashby CR Jr, et al. (2006). The novel dopamine D-3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 31:1393-1405.
76. Zangen A, Solinas M, Ikemoto S, Goldberg SR, Wise RA (2006). Two brain sites for cannabinoid reward. J Neurosci 26:4901-4907.